Article

Case Study Spotlights FCS as a Top-Ranking Performer in the Oncology Care Model

A recently published case study by Florida Cancer Specialists & Research Institute showcased the practice’s multi-year track record of delivering savings as a participant in the Oncology Care Model (OCM) when compared with OCM and non-OCM practices nationally.

Fort Myers, Florida — A recently published case study by Florida Cancer Specialists & Research Institute (FCS) showcased the practice’s multi-year track record of delivering savings as a participant in the Oncology Care Model (OCM) when compared with OCM and non-OCM practices nationally.

Amongst more than 125 participating practices nationwide, FCS emerged as a leader in value-based care oncology in having successfully reduced Medicare expenditures by nearly $170 million in aggregate.

“Our success in this program is indicative of the resources, dedication, investment and overall integrity of FCS’ commitment to healthcare reform,” said Michael Diaz, MD, president and managing physician, FCS. “Patients can find reassurance knowing that we have put elaborate measures in place to not only utilize state of the art technologies and therapeutics to maximize treatment outcomes but optimize care delivery to positively influence their overall cancer journey.”

Learn more.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Dr Sundar Jagannath
David Awad, PharmD, BCOP
Andrew Kuykendall, MD, Moffitt Cancer Center
Merrill H. Stewart, MD
Dr Margrit Wiesendanger
David Awad, PharmD, BCOP
H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview
Dr Margrit Wiesendanger
Ibrahim Aldoss, MD, associate professor, City of Hope
Manmeet Ahluwalia, MD, MBA, FASCO, chief of medical oncology, chief scientific officer, and deputy director of the Miami Cancer Institute of Baptist Health South Florida
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo